8-K: TELA Bio Q2 2026: Revenue Dips, Guidance Withdrawn

TELA Bio reported a 4% revenue decline in Q2 2026 to $19.3 million and withdrew its full-year guidance, citing headwinds in OviTex PRS volumes and price mix.

Summary

• TELA Bio reported second quarter 2026 revenue of $19.3 million, a 4% decrease compared to $20.2 million in the second quarter of 2025.
• The decline was attributed to lower OviTex PRS volumes and price mix headwinds, partially offset by international sales growth.
• Gross profit was $13.9 million (72% of revenue), an improvement from 70% in the prior year period, due to a tariff refund and lower inventory charges.
• Operating expenses remained flat at $23.2 million, with slight increases in meeting/training costs and professional fees offset by lower headcount and commission expenses.
• Loss from operations increased to $9.3 million from $9.1 million in the prior year period.
• Net loss widened to $11.3 million from $9.9 million in the prior year period.
• Cash and cash equivalents stood at $30.4 million as of June 30, 2026.
• The company has withdrawn its full-year 2026 financial guidance and will provide an update later.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues, withdrawal of guidance, and increased net loss, despite some operational improvements.

Positives

• International revenue grew by 26% over the prior year period.
• OviTex unit volume grew by 12% over the prior year period, indicating market share gains in hernia procedures.
• LiquiFix revenue increased by 39% over the prior-year period.
• Gross margin improved to 72% from 70% in the prior year period, driven by a tariff refund and reduced inventory write-downs.
• Operating expenses were managed effectively, remaining flat year-over-year despite some cost increases.

Negatives

• Total revenue for the second quarter of 2026 decreased by 4% to $19.3 million compared to $20.2 million in the second quarter of 2025.
• OviTex PRS unit volumes declined, contributing to the revenue decrease.
• Price and mix headwinds in hernia procedures negatively impacted financial performance.
• Loss from operations increased to $9.3 million from $9.1 million in the prior year.
• Net loss increased to $11.3 million from $9.9 million in the prior year.
• Cash and cash equivalents decreased significantly to $30.4 million from $50.8 million at the end of 2025.

Risks

• Continued competitive dynamics of bundling from larger competitors.
• Potential impact of macroeconomic conditions, including recessionary concerns, banking instability, interest rates, trade policies, and inflation.
• Demand for products could be affected by changes in surgical procedure volumes, outbreaks of illness, cybersecurity events, hospital closures, labor shortages, and supply chain disruptions.
• Ability to achieve or sustain profitability.
• Product development and manufacturing problems, capacity constraints, or production delays.
• Maintenance of coverage and adequate reimbursement for procedures using products.
• Product defects or failures.

Future Outlook

The company has withdrawn its full-year 2026 revenue guidance and will provide an update in the future as the new CEO assesses the business and strategic direction. The focus is on improving PRS performance, accelerating market share gains in hernia, and translating commercial productivity into sustainable growth, while also extending cash runway and aligning costs.

Management Comments

• "I am honored to join TELA Bio at such an exciting time in the Company's evolution. One reason I joined TELA is the superiority of our differentiated product portfolio. OviTex long-term data has continuously shown recurrence rates in the low single-digits, whereas other hernia repair materials have recurrence rates consistently 10 times higher than that. Unfortunately, the financial performance of the business does not reflect the superiority of the portfolio. Our second quarter revenue was negatively impacted by a decline in OviTex PRS volumes and continued price and mix headwinds in hernia procedures."
• "In response, we have returned to a sales structure designed to reinforce cross-selling among our field teams, and with a clear focus on returning to growth in the second half the year."
• "We also continue to battle against the competitive dynamics of bundling from our largest competitors and to combat this, we have upgraded talent within our Market Access and Contracting team."
• "We are encouraged by several indicators of progress across the business. Hernia unit volumes grew 12% year over year, demonstrating continued procedural market share gains, while ASP and procedure mix begin to stabilize. International revenue also continued to grow, and our field organization is progressing toward the productivity levels we expected as newer territory managers gain experience."
• "Given the confluence of these dynamics, we are withdrawing our full year 2026 revenue guidance as I fully assess the business and strategic direction. What is clear to me is that as we move through the second half of the year, we must improve PRS performance, accelerate our market share gains in hernia, and translate the increasing productivity of our commercial organization into sustainable top-line growth. At the same time, we will take decisive action to extend our cash runway and better align our cost structure with our top line. We are focused on disciplined execution and creating long-term value for all our stakeholders."

Industry Context

StockSavvy.ai notes that TELA Bio operates in the competitive medical technology sector, specifically focusing on soft-tissue reconstruction. The company faces challenges from larger competitors employing bundling strategies and price/mix headwinds in the hernia repair market, a segment where product differentiation and long-term clinical outcomes are critical.

Management Changes

Stakeholder Impact

• Shareholders: Potential negative impact due to declining revenue, increased net loss, withdrawal of guidance, and reduced cash reserves, which may affect stock price and future returns.
• Employees: Potential impact from cost structure alignment and focus on disciplined execution, which could include workforce adjustments.
• Customers/Hospitals: Continued provision of soft-tissue reconstruction solutions, with efforts to reinforce cross-selling and improve market share.
• Creditors: The company's cash position and increased net loss could be a concern, though long-term debt is significant.

Next Steps

• Assess the business and strategic direction under new CEO.
• Improve OviTex PRS performance.
• Accelerate market share gains in hernia procedures.
• Translate commercial organization productivity into sustainable top-line growth.
• Take decisive action to extend cash runway.
• Better align cost structure with top-line performance.
• Provide an update on full-year 2026 guidance in the future.

Key Dates

Recommendation

The withdrawal of guidance and declining revenue are significant negatives. However, the improved gross margin, international growth, and market share gains in specific product lines (OviTex unit volume, LiquiFix revenue) suggest underlying operational improvements and potential for recovery. The appointment of a new CEO to reassess strategy warrants a 'hold' to observe the impact of their initiatives before making a more definitive investment decision.

Keywords

soft-tissue reconstruction, medical technology, hernia repair, OviTex, LiquiFix, financial results, revenue, guidance